17 results about "Hyperphosphatemia" patented technology

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

The invention discloses a dietary compound containing resveratrol and application of the dietary compound in improvement of inflammatory injury of diabetic nephropathy, and belongs to the field of functional foods and dietary supplements. The L-WPI is taken as a carrier, so that the phosphorus load of a final product is reduced from the source, the problem that the hyperphosphatemia risk of a DKD patient is possibly aggravated by a conventional whey protein raw material is solved, and the L-WPI is more suitable for nutrition intervention of people with renal hypofunction. The L-WPI-Res compound constructed through heat treatment induction can effectively protect Res from being excessively degraded in a harsh stomach acidic and enzymatic hydrolysis environment, realizes stomach stability and intestinal targeted release, improves the biological accessibility of the compound in a small intestine stage by 20-35% compared with a free monomer, fundamentally solves the bottleneck problem of low oral availability of polyphenol compounds, and has a wide application prospect. Meanwhile, the L-WPI-Res-55 DEG C compound has a synergistic enhancement effect in two aspects of regulating blood sugar potential and relieving inflammation.

The present application relates to the technical field of medicine and chemical industry, in particular to a kind of alginate / nano lanthanum hydroxide composite microspheres and its preparation method and application.The composite microspheres use sodium alginate as organic matrix material, and nano lanthanum hydroxide as inorganic filling phase, which are prepared by electrospray technology, and can realize the uniform dispersion and wrapping of nano lanthanum hydroxide in alginate microspheres.The size of the composite microspheres can be adjusted as needed between 235.5 μm and 748.4 μm, and the mass ratio of alginate to nano lanthanum hydroxide can be adjusted as needed within 1: (0.5-1.5).The composite microspheres of the present application have a phosphorus binding capacity of 41.0 mg / g-90.0 mg / g in a gastric acid environment with pH=2, and excellent phosphorus binding ability, which can be used as an oral phosphorus binding agent for the treatment of hyperphosphatemia, providing a new technical solution for clinical intervention of hyperphosphatemia.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are a compound that is a parathyroid hormone receptor 1 agonist and a method useful for preventing or treating osteoporosis, fractures, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia, or neoplastic calcification.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods of using them for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

Disclosed herein is a compound or salt thereof comprising: (a) a first polymer; (b) a second polymer operably linked to the first polymer; and (c) a metal complex operably linked to the second polymer. Also disclosed herein are devices and materials comprising the compound as well as methods of using the compound, devices and materials for detecting ions such as phosphate, methods for removing ions such as phosphate from aqueous solutions or mixtures, and methods for treating hyperphosphatemia.

Disclosed herein are iron complexes and salts thereof comprising a compound of formula (I) as well as materials and devices comprising one or more iron complexes or salts thereof of formula I. Also disclosed herein are methods of using the iron complexes of formula I or salts thereof, such as methods for detecting ions such as phosphate, methods for removing ions such as phosphate from aqueous solutions or mixtures, and methods for treating hyperphosphatemia.

The application provides application of basic lanthanum oxide in preparation of a medicine for treating hyperphosphatemia or a disease related to hyperphosphatemia, and belongs to the technical field of medicines.The application provides application of basic lanthanum oxide in preparation of a medicine for treating hyperphosphatemia or a disease related to hyperphosphatemia, and the application adopts basic lanthanum oxide to prepare the medicine for treating hyperphosphatemia or the disease related to hyperphosphatemia; the basic lanthanum oxide has a higher lanthanum content, which can reach 80.8%, and is developed into the medicine for treating hyperphosphatemia or the disease related to hyperphosphatemia; the medicine has a smaller use amount or preparation specification in combination with the use amount of the medicine for the same amount of phosphate in blood of a hyperphosphatemia patient, is beneficial to improving the compliance of the patient, and has a better phosphorus-lowering effect.

Provided is the use of lanthanum oxyhydroxide in the preparation of a drug for treating hyperphosphatemia or a disease associated with hyperphosphatemia. The lanthanum oxyhydroxide is used for the preparation of a drug for treating hyperphosphatemia or a disease associated with hyperphosphatemia, wherein lanthanum oxyhydroxide has a relatively high lanthanum content of up to 80.8%, and accordingly, a relatively small dosage or formulation specification is required to bind the same amount of phosphate in the blood of a patient having hyperphosphatemia, which is beneficial for improving patient compliance, and same also exhibits a good phosphorus-lowering effect.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a low-potassium low-phosphorus protein component for special medical purposes and a preparation method thereof. The protein component is of a liquid ready-to-use type, and comprises the following components on the basis of 100 mL of total volume: 10.0-12.0 g of separated whey protein powder; and 0.05 to 0.15 g of stevioside. 0.20 to 0.30 g of a compound stabilizer; and the balance of water. The compound stabilizer is prepared from phospholipid and xanthan gum. The separated whey protein powder with low phosphorus and potassium content and specific calcium content is selected as a core protein source, so that the final product has extremely low phosphorus-protein ratio and potassium content. The phosphorus intake brought by the product is obviously lower than that of commercially available like products, and the kidney metabolism burden and the hyperphosphatemia risk of patients are greatly relieved. The phospholipid and the xanthan gum in a specific mass ratio are used as a compound stabilizer, and the phospholipid is used as an emulsifier, so that protein particles can be effectively wrapped, and aggregation is prevented.

The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.

The present invention provides a metal-organic framework (MOF) that finds utility in the treatment or prevention of hyperphosphatemia, wherein the MOF comprises a plurality of metal ions, each coordinated to a plurality of organic ligands, and wherein the plurality of metal ions comprises Zr4+ ions, Fe3+ ions, or a combination of Zr4+ and Fe3+ ions, and the plurality of organic ligands are selected from one or more members of the group consisting of a compound according to formula (I) as defined herein; a C2-6alkane substituted by two carboxylate groups and optionally substituted by one or two OH groups; a C4-6alkene substituted by two carboxylate groups; a benzenedicarboxylate optionally substituted by one or two NH2 groups; a benzenetricarboxylate; a 5-6 membered heteroaromatic ring comprising 1 or 2 atoms selected from the group consisting of N, S and O, wherein said heteroaromatic ring is substituted by two carboxylate groups; cyclohexane substituted by two carboxylate groups; and cystinate; or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides a pharmaceutical composition comprising a MOF of the present invention.